Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of April 2018. The report announces topline results from a Phase IIa investigator-initiated study conducted at Yale University regarding the Company's Tourette Syndrome (TS) program, THX-110.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on clinical trial results and does not contain financial statements.
Material Changes and Clinical Results
The primary material update is the successful completion of a single-arm, open-label Phase IIa study involving 16 subjects with medication-refractory Tourette Syndrome. Key findings include:
- Tic Reduction: Subjects experienced a significant reduction in tic symptoms, with a mean difference in the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS) of 7.9 (p=0.002).
- Percentage Improvement: The study resulted in an average tic reduction of 21% across the sample.
- Responder Rate: Six of the 16 subjects (37.5%) achieved a response defined as a greater than 25% reduction in YGTSS-TTS.
- Comorbidities: THX-110 demonstrated no significant effects on comorbid ADHD, anxiety, depression, or OCD symptoms.
- Safety and Tolerability: The medication was generally well-tolerated. Only two subjects stopped treatment early (one due to sedation, one due to lack of improvement).
- Extension: Twelve of the 16 subjects elected to continue into a 24-week extension phase, which is nearing completion.
Guidance, Outlook, and Risks
Based on these results, management intends to initiate a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of daily oral THX-110 in treating adults with TS. Complete results are scheduled for presentation at the 2018 European Society for the Study of Tourette Syndrome meeting in Copenhagen, Denmark. The filing does not explicitly list financial risks or contingencies, though the reliance on future clinical trial success is implied.
Investor Verification Checklist
- Verify the transition from the open-label Phase IIa study to the planned randomized, double-blind, placebo-controlled study.
- Monitor the completion and data release of the 24-week extension phase for the 12 continuing subjects.
- Review the full data presentation at the 2018 European Society for the Study of Tourette Syndrome meeting for detailed safety and efficacy profiles.
- Confirm the Company's capital position and funding strategy to support the upcoming Phase II/III trials, as no financial data was provided in this filing.